Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report

Stephanie Lheureux, Carolyn McCourt, B. J. Rimel, Linda Duska, Gini Fleming, Helen Mackay, David Mutch, Sarah M. Temkin, Jean Lynn, Elise C. Kohn

Research output: Contribution to journalArticlepeer-review

Abstract

The incidence of endometrial cancer (EC) in the U.S. has been rising, from an estimated annual incidence of 49,560 in 2013 to 61,380 in 2017. Meanwhile, the SEER-based relative survival of women with EC in the U.S. has remained flat [82.3% from 1987 to 1989, 82.8% from 2007 to 2013] and our recent increased understanding of EC biology and subtypes has not been translated into therapeutic advances. The U.S. National Cancer Institute (NCI) therefore convened a Uterine Clinical Trials Planning Meeting in January 2016 to initiate and accelerate design of molecularly-targeted EC trials. Prior to the meeting a group of experts in this field summarized available data, emphasizing data on human samples, to identify potentially actionable alterations in EC, and the results of their work has been separately published. The Clinical Trials Meeting planners focused on discussion of (1) novel trial designs, including window-of opportunity trials and appropriate control groups for randomized trials, (2) targets specific to serous carcinoma and promises and pitfalls of separate trials for women with tumors of this histology (3) specific recommendations for future randomized trials.

Original languageEnglish
JournalGynecologic oncology
DOIs
StateAccepted/In press - Jan 1 2018

Keywords

  • Clinical trial
  • Endometrial cancer
  • Molecular target
  • Serous

Fingerprint Dive into the research topics of 'Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report'. Together they form a unique fingerprint.

Cite this